Premium
Platelet transfusion therapy
Author(s) -
Goodnough Lawrence Tim
Publication year - 2001
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.1011
Subject(s) - apheresis , platelet , medicine , plateletpheresis , platelet transfusion , blood product , intensive care medicine , yield (engineering) , immunology , surgery , materials science , metallurgy
Abstract The relative merits of apheresis platelets and platelet concentrates are undergoing debate due to evolving issues of safety, inventory, and cost. The application of photochemical inactivation technology may eliminate any rationale for the use of apheresis platelets rather than pooled platelet concentrates, so that the relative merits of these two alternatives will be debated over costs and inventory. Doses of apheresis platelets are determined by donor platelet count and by platelet yield. The generation of a platelet apheresis inventory has been accompanied by a decline in whole blood inventory; research into the impact of these distinct donor pools on national blood policy is needed. J. Clin. Apheresis. 16:43‐48, 2001. © 2001 Wiley‐Liss, Inc.